Medical affairs: The power behind redefining commercialization

Medical affairs commercialization, integrating science in pharma, redefining medical affairs roles, strategic medical affairs leadership, early engagement with payers, pharmaceutical commercialization strategies, upskilling in medical affairs, medical aff

In March 2024, Envision Pharma Group held a Medical Affairs Professional Society (MAPS) Americas roundtable with leaders discussing the role of science in commercialization strategies and the importance of integrating robust scientific understanding into the commercial journey. Envision revisite…

Aug 2^nd • 3 mins read

AI-powered real-world evidence: Strategically enhancing value and access

Oncology, Clinical Development, Targeted Therapy, Immunotherapy, Genomic Profiling, CAR-T Cell Therapy, Precision Medicine

Real-world evidence (RWE) complements traditional randomized controlled trials by providing insights from diverse data sources, helping healthcare decision-makers with coverage, reimbursement, and treatment guidelines. Artificial intelligence (AI) and natural language processing (NLP) are pivotal…

Aug 22^nd • 5 mins read

Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement

oncology, research, reporting, adverse events, clinical trials

Monitoring patient safety during clinical trials is crucial to protect research participants and future patients. Under current regulations for investigational new drugs (INDs), sponsors must report certain serious adverse events (AEs) to the FDA and all participating investigators quickly.…

Feb 20^th • 3 mins read